Despite declining demand for its COVID-19 products, Pfizer reported fourth-quarter revenue that surpassed analyst expectations. The pharmaceutical giant saw a drop in sales of its COVID vaccine and antiviral pill. However, strong performance from its respiratory syncytial virus vaccine, Abrysvo, and oncology biosimilars helped offset the losses, indicating a strategic shift.

Sales of Abrysvo, a respiratory syncytial virus vaccine, surged by 136% globally, driven by international market uptake. While overall operational revenues decreased slightly, Pfizer's adjusted earnings per share exceeded projections. The company is actively diversifying its portfolio and anticipates approximately 20 pivotal drug trials this year, focusing on key therapeutic areas.

Looking ahead, Pfizer reaffirmed its revenue guidance for the current year. The firm is also exploring new avenues, with an experimental obesity drug showing promising results in a mid-stage trial. This follows Pfizer's acquisition of Metsera, signaling the company’s intent to strengthen its presence in the weight-loss market.

Pfizer's performance reflects the changing market dynamics post-pandemic and its efforts to adapt. The company faces headwinds from lower COVID-19 product demand and potential impacts from policies aimed at reducing prescription medicine costs. Investors will be watching how Pfizer executes its diversification strategy and clinical trial pipeline.